Federal Circuit rejects ADHD generic drug challenge

08-07-2022

Federal Circuit rejects ADHD generic drug challenge

rafapress / Shutterstock.com

A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.


Teva, Tris, Actavis, ADHD, generics, Ritalin, methylphenidate, Quillivant XR, Federal Circuit

More on this story

Tris blocks Actavis’ ADHD generic
10-12-2020

LSIPR